Cover Image
市場調查報告書

主要已開發國家的老年癡呆症治療藥市場:由於對高齡化人口與疾病的理解改善,疾病修飾劑的需求增加

Alzheimer's Disease Therapeutics in Major Developed Markets to 2021 - Aging Population and Improved Disease Understanding Increase Demand for Disease Modifying Agents

出版商 GBI Research 商品編碼 353593
出版日期 內容資訊 英文 144 Pages
訂單完成後即時交付
價格
Back to Top
主要已開發國家的老年癡呆症治療藥市場:由於對高齡化人口與疾病的理解改善,疾病修飾劑的需求增加 Alzheimer's Disease Therapeutics in Major Developed Markets to 2021 - Aging Population and Improved Disease Understanding Increase Demand for Disease Modifying Agents
出版日期: 2016年02月01日 內容資訊: 英文 144 Pages
簡介

主要8個市場上的老年癡呆症治療藥市場,從2014年的52億美元,2021年增加到113億美元,預計以11.8%的年複合成長率 (CAGR) 成長。

本報告提供主要已開發國家的老年癡呆症治療藥市場相關調查分析、市場概要、上市產品、開發中產品、市場預測、交易和策略性整合等相關的系統性資訊。

第1章 目錄

第2章 簡介

  • 疾病概要
  • 流行病學
  • 症狀
  • 病因
  • 病理生理學
  • 分期
  • 診斷
  • 預後
  • 治療

第3章 上市產品

  • Aricept (donepezil)
  • Exelon (rivastigimine)
  • Razadyne (galanatamine)
  • Namenda/Ebixa/Axura/Abixa (memantine)
  • Cognex (tacrine)
  • Namzaric (memantine ER + donepezil)

第4章 熱圖:上市產品概要

第5章 開發中產品的開發

  • 開發平台的開發情形
  • 開發平台的作用機制
  • 臨床實驗
  • 有前途的開發平台分子

第6章 熱圖:開發中產品的概要

第7章 市場預測

  • 各地區市場

第8章 推動因素與阻礙

  • 推動因素
  • 障礙

第9章 策略性整合

  • 許可證交易
  • 主要的共同開發交易

第10章 附錄

圖表

目錄
Product Code: GBIHC399MR

Executive Summary

Alzheimer's Disease (AD) is an irreversible, progressive neurodegenerative disease, characterized by cognitive impairment, memory loss and functional decline. Symptoms typically begin to first appear in patients in their mid-sixties, with symptoms appearing in varying stages. The pathological features of AD comprise histopathological changes within the brain. Mild Cognitive Impairment (MCI) is a heterogeneous condition between normal cognition and dementia, whereby cognitive changes in mental abilities, such as memory or thinking, are affected. Almost all cases of AD begin with MCI, but it should be noted that not all patients with MCI go on to develop AD.

Although there is a high degree of failure and uncertainty within the R&D of AD drugs, the number of drugs in the pipeline is considerably high at 559. The majority of the pipeline products are novel drugs, with a total of seven repositioned and five generic drugs. This shows advancement in the progression of the different molecules being developed as therapeutic agents within the AD pipeline.

Scope

The AD market has a lack of therapeutic options.

  • Which classes of drug dominate the market?
  • What newly approved therapies have entered the market?
  • How do the leading marketed therapies compare clinically?
  • How will the new therapies be positioned in the treatment of AD?
  • How have selected late-stage pipeline therapies performed in clinical trials?
  • The pipeline contains a range of molecule types and molecular targets, including those that are well established in AD, and novel, first-in-class therapies.
  • Which molecular targets appear most frequently in the pipeline?
  • AD clinical trials have an overall attrition rate of 94%.
  • What are the failure rates for individual Phases of clinical development?
  • How do AD clinical trial characteristics, including failure rate, duration, and size compare against respiratory and industry averages?
  • The AD market is forecast to rise from a value of $5.2 billion in 2014 to $11.3 billion in 2021, at a CAGR of 11.8% across the eight major markets assessed.
  • How much of a role will disease prevalence and new product approvals play in market growth?
  • Will generic competition have a significant impact on the market over the forecast period?
  • There have been 170 licensing deals and 104 co-development deals pertaining to AD products since 2006.
  • Which territories show the most deal activity?
  • What were the trends in deal completion by product stage of development?
  • What were the conditions of the key licensing or co-development deals to take place in AD?

Reasons to buy

This report will allow you to -

  • Understand the current clinical and commercial landscape through a comprehensive study of disease pathogenesis, diagnosis, prognosis, and the current treatment algorithm used in AD.
  • Assess the safety and efficacy of current treatment options, with extensive product profiles on prominent marketed therapies, and a heatmap directly comparing safety and efficacy data.
  • Analyze the AD pipeline and stratify by stage of development, molecule type, and molecular target. The most promising late-stage therapies are profiled and assessed in terms of clinical performance and competitiveness, alongside a single-product forecast.
  • Predict growth in market size in eight major markets, with in-depth market forecasting from 2014 to 2021. The forecasts will provide an understanding of how epidemiology trends, new drug entries, and patent expirations will influence market value.
  • Identify commercial opportunities in the AD deals landscape by analyzing trends in licensing and co-development deals, and by profiling the most significant deals that have occurred in this indication in recent years.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Disease Introduction
  • 2.2. Epidemiology
  • 2.3. Symptoms
  • 2.4. Etiology
  • 2.5. Pathophysiology
  • 2.6. Disease Stages
  • 2.7. Diagnosis
  • 2.8. Prognosis
  • 2.9. Treatment
    • 2.9.1. Treatment Algorithm
    • 2.9.2. Mild-to-Moderate AD
    • 2.9.3. Moderate-to-Severe AD

3. Marketed Products

  • 3.1. Aricept (donepezil) - Eisai
  • 3.2. Exelon (rivastigimine) - Novartis
  • 3.3. Razadyne (galanatamine) - Janssen
  • 3.4. Namenda/Ebixa/Axura/Abixa (memantine), Merz Pharma/Lundbeck/Forest/Daiichi Sankyo
  • 3.5. Cognex (tacrine) - Shiniogi
  • 3.6. Namzaric (memantine ER + donepezil), Actavis-Adamas

4. Heat Map - Marketed Products Overview

5. Pipeline Product Developments

  • 5.1. The Pipeline Development Landscape
  • 5.2. Mechanisms of Action in the Pipeline
  • 5.3. Clinical Trials
    • 5.3.1. Failure Rate
    • 5.3.2. Clinical Trial Duration
    • 5.3.3. Clinical Trial Size
    • 5.3.4. Competitive Clinical Trials Metric Analysis
  • 5.4. Promising Pipeline Molecules
    • 5.4.1. MK-8931 - Merck & Co.
    • 5.4.2. LMTX (methylthioninium chloride) - TauRX Therapeutics
    • 5.4.3. AZD3293 - AstraZeneca
    • 5.4.4. AB1010 - AB Science
    • 5.4.5. BIIB037 - Biogen
    • 5.4.6. TP488 - vTv Therapeutics
    • 5.4.7. EVP-6124 - FORUM Pharmaceuticals
    • 5.4.8. LuAE58054 - Lundbeck
    • 5.4.9. Gantenerumab (R-1540/RG-1450) - Roche

6. Heat Map - Pipeline Products Overview

7. Market Forecast to 2021

  • 7.1. Geographical Markets
    • 7.1.1. Global Market
    • 7.1.2. North America
    • 7.1.3. European Union Five
    • 7.1.4. Japan

8. Drivers and Barriers

  • 8.1. Drivers
    • 8.1.1. Rising Prevalence
    • 8.1.2. Increasing Public and Policy-Maker Awareness
    • 8.1.3. Innovation in Pipeline
    • 8.1.4. Growing Understanding of AD Pathophysiology
  • 8.2. Barriers
    • 8.2.1. Sales Erosion by Generics
    • 8.2.2. High Clinical Failure RatesAD has a particularly high clinical trial failure rate.
    • 8.2.3. Drug Testing in Patients with Established AD and Advanced Neurodegeneration
    • 8.2.4. Low Diagnosis and Treatment Rate

9. Strategic Consolidations

  • 9.1. Licensing Deals
    • 9.1.1. Cephalon Enters into Licensing Agreement with Mesoblast
    • 9.1.2. Lundbeck Enters into Licensing Agreement with Otsuka
    • 9.1.3. Roche Enters into Licensing Agreement with Prothera
    • 9.1.4. GlaxoSmithKline Enters into Licensing Agreement with AFFiRiS
  • 9.2. Major Co-development Deals
    • 9.2.1. Lundbeck Enters into Co-development Agreement with Otsuka
    • 9.2.2. GlaxoSmithKline Enters into Agreement with EPIX Pharma
    • 9.2.3. Evotec Enters into Co-development Agreement with Roche
    • 9.2.4. Pfizer Enters into Co-development Agreement with Medivation

10. Appendix

  • 10.1. All Pipeline Drugs by Phase
    • 10.1.1. Discovery
    • 10.1.2. Preclinical
    • 10.1.3. Phase I
    • 10.1.4. Phase II
    • 10.1.5. Phase III
    • 10.1.6. Market Forecasts to 2021
  • 10.2. Bibliography
  • 10.3. Abbreviations
  • 10.4. Research Methodology
    • 10.4.1. Secondary Research
    • 10.4.2. Marketed Product Profiles
    • 10.4.3. Late-Stage Pipeline Candidates
    • 10.4.4. Comparative Efficacy and Safety Heat Map for Marketed and Pipeline Products
    • 10.4.5. Product Competitiveness Framework
    • 10.4.6. Pipeline Analysis
    • 10.4.7. Forecasting Model
    • 10.4.8. Deals Data Analysis
  • 10.5. Contact Us
  • 10.6. Disclaimer

List of Tables

  • Table 1: Alzheimer's Disease Therapeutics Market, Symptoms of Alzheimer's Disease at Different Stages of Disease
  • Table 2: Alzheimer's Disease Therapeutics Market, Symptoms of Mild Cognitive Impairment
  • Table 3: Alzheimer's Disease Therapeutics Market, Global Deterioration Scale for Alzheimer's Disease
  • Table 4: Alzheimer's Disease Therapeutics Market, Mini-Mental State Exam
  • Table 5: Alzheimer's Disease Therapeutics Market, Alzheimer's Disease Assessment Scale Cognitive Subscale
  • Table 6: Alzheimer's Disease Therapeutics Market, Mild Cognitive Impairment Diagnosis Guidelines
  • Table 7: Management of AD Symptoms
  • Table 8: AD Market, Global, Pipeline Products, Discovery, 2016
  • Table 9: AD Market, Global, Pipeline Products, Preclinical, 2016
  • Table 10: AD Market, Global, Pipeline Products, Phase I, 2016
  • Table 11: AD Market, Global, Pipeline Products, Phase II, 2016
  • Table 12: AD Market, Global, Pipeline Products, Phase III, 2016
  • Table 13: MCI Market, Global, Market Forecast, 2014-2021
  • Table 14: AD Market, Global, Market Forecast, 2014-2021
  • Table 15: MCI & AD Combined Market, Global, Market Forecast, 2014-2021
  • Table 16: MCI Market, US, Market Forecast, 2014-2021
  • Table 17: AD Market, US, Market Forecast, 2014-2021
  • Table 18: MCI & AD Market, US, Market Forecast, 2014-2021
  • Table 19: MCI Market, Canada, Market Forecast, 2014-2021
  • Table 20: AD Market, Canada, Market Forecast, 2014-2021
  • Table 21: MCI & AD Combined Market, Canada, Market Forecast, 2014-2021
  • Table 22: MCI Market, UK, Market Forecast, 2014-2021
  • Table 23: AD Market, UK, Market Forecast, 2014-2021
  • Table 24: MCI & AD Combined Market, UK, Market Forecast, 2014-2021
  • Table 25: MCI Market, France, Market Forecast, 2014-2021
  • Table 26: AD Market, France, Market Forecast, 2014-2021
  • Table 27: MCI & AD Market Combined, France, Market Forecast, 2014-2021
  • Table 28: MCI Market, Germany, Market Forecast, 2014-2021
  • Table 29: AD Market, Germany, Market Forecast, 2014-2021
  • Table 30: MCI & AD Combined Market, Germany, Market Forecast, 2014-2021
  • Table 31: MCI Market, Italy, Market Forecast, 2014-2021
  • Table 32: AD Market, Italy, Market Forecast, 2014-2021
  • Table 33: MCI & AD Combined Market, Italy, Market Forecast, 2014-2021
  • Table 34: MCI Market, Spain, Market Forecast, 2014-2021
  • Table 35: AD Market, Spain, Market Forecast, 2014-2021
  • Table 36: MCI & AD Combined Market, Spain, Market Forecast, 2014-2021
  • Table 37: MCI Market, Japan, Market Forecast, 2014-2021
  • Table 38: AD Market, Japan, Market Forecast, 2014-2021
  • Table 39: MCI & AD Combined Market, Japan, Market Forecast, 2014-2021

List of Figures

  • Figure 1: Alzheimer's Disease Therapeutics Market, Treatment Algorithm of Alzheimer's Disease
  • Figure 2: Alzheimer's Disease Therapeutics Market, Heat Map for Marketed Products
  • Figure 3: Alzheimer's Disease Therapeutics Market, Overall Pipeline
  • Figure 4: Alzheimer's Disease Therapeutics Market, Pipeline by Mechanism of Action (%)
  • Figure 5: Alzheimer's Disease Therapeutics Market, Clinical Trial Failure Rates by Phase (%)
  • Figure 6: Alzheimer's Disease Therapeutics Market, Clinical Trial Failure Rates by Mechanism of Action, (%)
  • Figure 7: Alzheimer's Disease Therapeutics Market, Clinical Trial Duration by Molecule Type (months)
  • Figure 8: Alzheimer's Disease Therapeutics Market, Clinical Trial Duration by Mechanism of Action (months)
  • Figure 9: Alzheimer's Disease Therapeutics Market, Clinical Trial Size per Product by Molecule Type (participants)
  • Figure 10: Alzheimer's Disease Therapeutics Market, Clinical Trial Size per Product by Mechanism of Action (participants)
  • Figure 11: Alzheimer's Disease Therapeutics Market, Clinical Trial Size per Trial by Molecule Type (participants)
  • Figure 12: Alzheimer's Disease Therapeutics Market, Clinical Trial Size per Trial by Mechanism of Action (participants)
  • Figure 13: Alzheimer's Disease Therapeutics Market, Global, Comparison of Average Trial Metrics by Phase and Molecule Type
  • Figure 14: Alzheimer's Disease Therapeutics Market, Global, Comparison of Average Trial Metrics by Phase and Mechanism of Action
  • Figure 15: Alzheimer's Disease Therapeutics Market, Global, Verubecestat Market Forecast ($m), 2018-2021
  • Figure 16: Alzheimer's Disease Therapeutics Market, Global, LMTX Market Forecast ($m), 2017-2021
  • Figure 17: Alzheimer's Disease Market, Global, AZD3293 Market Forecast ($m), 2019-2021
  • Figure 18: Alzheimer's Disease Therapeutics Market, Global, Masitinib Market Forecast ($m), 2017-2021
  • Figure 19: Alzheimer's Disease Therapeutics Market, Global, Aducanumab Market Forecast ($m), 2019-2021
  • Figure 20: Alzheimer's Disease Therapeutics Market, Global, Azeliragon Market Forecast ($m), 2017-2021
  • Figure 21: Alzheimer's Disease Therapeutics Market, Global, Encenicline Hydrochloride Market Forecast ($m), 2017-2021
  • Figure 22: Alzheimer's Disease Therapeutics Market, Global, Idalopirdine Market Forecast ($m), 2017-2021
  • Figure 23: Alzheimer's Disease Therapeutics Market, Global, Gantenerumab Market Forecast ($m), 2020-2021
  • Figure 24: Alzheimer's Disease Therapeutics Market, Heat Map for Marketed Products
  • Figure 25: Alzheimer's Disease and Mild Cognitive Impairment Therapeutics Markets, Global, Treatment Patterns ('000), 2014-2021
  • Figure 26: Alzheimer's Disease and Mild Cognitive Impairment Aggregate Therapeutics Market, Global, Treatment Patterns ('000), 2014-2021
  • Figure 27: Alzheimer's Disease and Mild Cognitive Impairment Therapeutics Markets, Global, Market Size ($bn), 2014-2021
  • Figure 28: Alzheimer's Disease and Mild Cognitive Impairment Aggregate Therapeutics Market, Global, Market Size ($bn), 2014-2021
  • Figure 29: Alzheimer's Disease and Mild Cognitive Impairment Therapeutics Markets, North America, Treatment Patterns ('000), 2014-2021
  • Figure 30: Alzheimer's Disease and Mild Cognitive Impairment Aggregate Therapeutics Market, North America, Treatment Patterns ('000), 2014-2021
  • Figure 31: Alzheimer's Disease Therapeutics Market, North America, Annual Cost of Therapy ($), 2014-2021
  • Figure 32: Alzheimer's Disease Therapeutics Market, North America, Market Size ($m), 2014-2021
  • Figure 33: Alzheimer's Disease and Mild Cognitive Impairment Aggregate Therapeutics Market, North America, Market Size, 2014-2021
  • Figure 34: Mild Cognitive Impairment Therapeutics Market, EU5, Treatment Patterns ('000), 2014-2021
  • Figure 35: Alzheimer's Disease Therapeutics Market, EU5, Treatment Patterns ('000), 2014-2021
  • Figure 36: Alzheimer's Disease and Mild Cognitive Impairment Aggregate Therapeutics Market, EU5, Treatment Patterns ('000), 2014-2021
  • Figure 37: Mild Cognitive Impairment Therapeutics Market, EU5, Annual Cost of Therapy ($), 2014-2021
  • Figure 38: Alzheimer's Disease Therapeutics Market, EU5, Annual Cost of Therapy ($), 2014-2021
  • Figure 39: Mild Cognitive Impairment Therapeutics Market, EU5, Market Size ($m), 2014-2021
  • Figure 40: Alzheimer's Disease Therapeutics Market, EU5, Market Size ($m), 2014-2021
  • Figure 41: Alzheimer's Disease and Mild Cognitive Impairment Aggregate Therapeutics Market, EU5, Market Size ($m), 2014-2021
  • Figure 42: Alzheimer's Disease and Mild Cognitive Impairment Therapeutics Markets, Japan, Treatment Patterns ('000), 2014-2021
  • Figure 43: Alzheimer's Disease and Mild Cognitive Impairment Aggregate Therapeutics Market, Japan, Treatment Patterns ('000), 2014-2021
  • Figure 44: Mild Cognitive Impairment Therapeutics Market, Japan, Annual Cost of Therapy ($), 2014-2021
  • Figure 45: Alzheimer's Disease Therapeutics Market, Japan, Annual Cost of Therapy ($), 2014-2021
  • Figure 46: Mild Cognitive Impairment Therapeutics Market, Japan, Market Size ($bn), 2014-2021
  • Figure 47: Alzheimer's Disease Therapeutics Market, Japan, Market Size ($m), 2014-2021
  • Figure 48: Alzheimer's Disease and Mild Cognitive Impairment Aggregate Therapeutics Market, Japan, Market Size ($bn), 2014-2021
  • Figure 49: Alzheimer's Disease Therapeutics Market, Licensing Deals by Value, 2006-2015
  • Figure 50: Alzheimer's Disease Therapeutics Market, Global, Number of Disclosed and Undisclosed Licensing Deals by Year, Aggregate Deal Value ($bn) and Aggregate Upfront Payment Value ($bn), 2006-2015
  • Figure 51: Alzheimer's Disease Therapeutics Market, Global, Licensing Deals by Stage of Development, Deal Value ($m) and Upfront Payment Value ($m), 2006-2015
  • Figure 52: Alzheimer's Disease Therapeutics Market, Global, Licensing Deals by Molecule Type and Value ($), 2006-2015
  • Figure 53: Alzheimer's Disease Therapeutics Market, Global, Licensing Deals by Molecular Target and Aggregate Value ($bn), 2006-2015
  • Figure 54: Alzheimer's Disease Therapeutics Market, Global, Co-development Deals by Value, 2006-2015
  • Figure 55: Alzheimer's Disease Therapeutics Market, Global, Number of Disclosed and Undisclosed Co-development Deals by Year, Aggregate Deal Value ($m) and Aggregate Upfront Payment Value ($m), 2006-2015
  • Figure 56: Alzheimer's Disease Therapeutics Market, Global, Co-development Deals by Stage of Development, Deal Value ($) and Upfront Payment Value ($m), 2006-2015
  • Figure 57: Alzheimer's Disease Therapeutics Market, Global, Co-development Deals by Molecule Type and Value ($), 2006-2015
  • Figure 58: Alzheimer's Disease Therapeutics Market, Global, Licensing Deals by Molecular Target and Aggregate Value ($bn), 2006-2015
Back to Top